pharmaceuticalcommerce5d
ImmunityBio to Supply Recombinant BCG to Alleviate Tice BCG Shortage
FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.
GlobalData on MSN6d
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancer
ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...
Cancer Therapy Advisor5d
FDA Allows Use of Recombinant BCG Through Expanded Access Program
The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.
FDA authorizes ImmunityBio to provide rBCG to urologists amid shortages
ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...
Hosted on MSN6d
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies
Shares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after ...
Le Lézard6d
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
In a recent Sermo survey of 100 U.S. urologists, 57 percent indicated they were unable to treat patients in the last 12 months due to a lack of access to TICE ® BCG. The alternative BCG source ...
Investing6d
FDA approves expanded access for ImmunityBio's bladder cancer drug
to supply a new Bacillus Calmette-Guérin (BCG) source for bladder cancer treatment in the U.S. This development comes as a response to the shortage of TICE® BCG, which has affected patient treatment ...